Intellipharmaceutics International Inc. (IPCI)

[WeeZuhl]

Good Question

WeeZuhl, Previous gelling patents invalid for obviousness. I think I read previous gelling patents by Purdue were found invalid because it was obvious to anyone trained in that field in the year 2001. It is obvious to increase the viscosity to prevent injection by syringe.

WeeZuhl, so why did you bring up 50% PEO, since the gelling patent does not specify any amount of PEO?

I used 50% because all of the examples of extended-release oxycodone in the PODRAS patent use more than 50% w/w % of PEO. The percentage of PEO by weight goes up or down depending on the milligrams of oxycodone in the example. Thus, the total weight of the core remains constant. (Also, total weight of mitochondrial poison blue dye #1 remains constant in the examples (15mg).)


Again, and I cannot stress this enough, I have no idea if Purdue will win this case, and I repeatedly have said their best course of action would have been to do nothing and let the FDA block Rexista until at least August 2018. But what I take exception to is the repeated posts about how Rexista is based on some unique ADF technology that is patented and proprietary. It very simply IS NOT. It is not patented, and it is not unique, other than the poisonous blue dye, which we all know will never make it into the final formulation that gets approval. Take the blue dye out of Rexista, and what you're left with is very expensive generic OxyContin that can be chewed "like bubblegum."


Rexista might be the best to chew while in class, but it will never be "Best In Class."